The estimated Net Worth of Natalie Sacks is at least $1.83 Millón dollars as of 18 May 2020. Dr Sacks owns over 1,522 units of Harpoon Therapeutics stock worth over $1,087,821 and over the last 8 years he sold HARP stock worth over $108,999. In addition, he makes $633,350 as Chief Medical Offer at Harpoon Therapeutics.
Dr has made over 19 trades of the Harpoon Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 1,522 units of HARP stock worth $3,227 on 18 May 2020.
The largest trade he's ever made was exercising 24,150 units of Harpoon Therapeutics stock on 14 October 2019 worth over $51,198. On average, Dr trades about 3,273 units every 31 days since 2016. As of 18 May 2020 he still owns at least 47,276 units of Harpoon Therapeutics stock.
You can see the complete history of Dr Sacks stock trades at the bottom of the page.
Dr. Natalie R. Sacks M.D. is the Chief Medical Offer at Harpoon Therapeutics.
As the Chief Medical Offer of Harpoon Therapeutics, the total compensation of Dr D at Harpoon Therapeutics is $633,350. There are 1 executives at Harpoon Therapeutics getting paid more, with Gerald McMahon having the highest compensation of $1,793,260.
Dr D is 56, he's been the Chief Medical Offer of Harpoon Therapeutics since . There are 4 older and 9 younger executives at Harpoon Therapeutics. The oldest executive at Harpoon Therapeutics, Inc. is Gerald McMahon, 65, who is the President, Chief Executive Officer, Director.
Natalie's mailing address filed with the SEC is C/O ZYMEWORKS INC., 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709.
Over the last 6 years, insiders at Harpoon Therapeutics have traded over $62,512,704 worth of Harpoon Therapeutics stock and bought 26,100,850 units worth $525,945,967 . The most active insiders traders include & Co., Inc.Merck Sharp & Do..., Ronald Hunt y Bioscience Plc Arix Bioscie.... On average, Harpoon Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $9,736,866. The most recent stock trade was executed by & Co., Inc.Merck Sharp & Do... on 11 March 2024, trading 21,397,205 units of HARP stock currently worth $492,135,715.
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Harpoon Therapeutics executives and other stock owners filed with the SEC include: